-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HyLislqWETIYM8CFEztPZ8hyf6POwroLGd2rEKt8TO3Ka9RqkEEvpJxwQHHexHvB jgHpkDCQ6LBRPD6fULwjvA== 0001279569-09-000148.txt : 20090204 0001279569-09-000148.hdr.sgml : 20090204 20090204130812 ACCESSION NUMBER: 0001279569-09-000148 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090204 FILED AS OF DATE: 20090204 DATE AS OF CHANGE: 20090204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOVASC INC CENTRAL INDEX KEY: 0001399708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53363 FILM NUMBER: 09567614 BUSINESS ADDRESS: STREET 1: 2135 13700 Mayfield place STREET 2: richmond british columbia CITY: Canada STATE: A1 ZIP: 00000 BUSINESS PHONE: 604-270-4344 MAIL ADDRESS: STREET 1: 2135 13700 Mayfield place STREET 2: richmond british columbia CITY: Canada STATE: A1 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Medical Ventures Corp DATE OF NAME CHANGE: 20070516 6-K 1 neovasc6k.htm FORM 6-K neovasc6k.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of February, 2009
 
Commission File Number: 000-53363
 
NEOVASC INC.
(Exact name of Registrant as specified in its charter)
 
Suite 2135 - 13700 Mayfield Place
Richmond, British Columbia, Canada, V6V 2E4
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
x Form 20-F   o Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes o   No x
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _________
 
 
 
 
 
 
SUBMITTED HEREWITH
 
Exhibits
   Description
     
99.1
   News Release Dated February 4, 2009 - Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  NEOVASC INC.
  (Registrant)
     
Date: February 4, 2009 By: /s/ Alexei Marko
   
    Alexei Marko
  Title: Chief Executive Officer
 
EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 4, 2009 ex991.htm 
Exhibit 99.1
News release via Canada NewsWire, Vancouver 604-669-7764

	    Attention Business/Medical Editors:
	    Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line
	    Reinforcement Product

	    <<
	           -- Aegis Can Now Be Marketed for Use in European Union --
	                 -- Neovasc Also Announces Senior Management
	                         Changes and Issues Options --
	    >>

	    VANCOUVER, Feb. 4 /CNW/ - Neovasc Inc. (TSXV: NVC), a new specialty
vascular device company, today announced that it has received CE mark approval
for Peripatch(TM) Aegis, its biocompatible product designed to reduce
complications from endoscopic surgery. This approval enables the company to
begin marketing Aegis products for sale in the European Union. Peripatch Aegis
is a buttressing material designed to reinforce the staple line and prevent
bleeding and leaks during bariatric and thoracic endoscopic surgical
procedures. Peripatch Aegis products will be marketed in Europe through
Neovasc's network of independent distributors.
	    "Leakage in endoscopic procedures can result in serious complications for
patients, so we specifically designed Peripatch Aegis to enable endoscopic
surgeons to reinforce surgical staple lines efficiently and effectively," said
Alexei Marko, chief executive officer of Neovasc. "We are pleased to have
received regulatory clearance to now make this superior product available to
surgeons in Europe."
	    Separately, Neovasc also announced changes to its senior management team.
The company is pleased to announce that Cynthia Roney has been appointed to
the expanded role of vice president, sales and marketing, adding the
responsibilities of the former position of vice president, sales to her
portfolio. In addition, Neovasc named Fabio De Pasquale as director,
regulatory affairs. Mr. De Pasquale brings over 18 years of industry
experience to his new role.
	    In addition, Neovasc announced today that on February 2, 2009 it granted
a total of 427,500 options to the directors and 60,000 options to the senior
management of the company. Of these options issued, 312,500 have an exercise
price of $0.40, expire five years from the grant date and vest over four years
according to the following schedule: 20% vest on the grant date and 20% vest
on each of the next four anniversaries of the grant date. The remaining
175,000 options are granted at $0.40, expire after five years and vest
immediately. The market price at close of February 2, 2009 was $0.40. The
grant of these options is in accordance with the existing stock option plan.

	    About Neovasc Inc.

	    Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty
vascular device company that develops, manufactures and markets medical
devices for the rapidly growing vascular and surgical marketplace. Neovasc is
comprised of the former Medical Ventures, Neovasc Medical Ltd. and B-Balloon
Ltd. The company's current products include, Metricath(R) for intravascular
measurement and Peripatch(TM) surgical tissue and staple line reinforcement
products. Neovasc has a development pipeline of innovative new products, and
provides contract medical device development and manufacturing services. For
more information, visit: www.neovasc.com.

	    Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.

	    %CIK: 0001399708

	    /For further information: Corporate contact: Neovasc Inc., Chris Clark,
(604) 248-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners,
Barbara Lindheim, (212) 918-4650/
	    (NVC.)

CO:  Neovasc Inc.

CNW 07:32e 04-FEB-09
-----END PRIVACY-ENHANCED MESSAGE-----